Divine Aleru, Microbiome Medicine Research Coordinator

This study demonstrates the promising role of hyperbaric oxygen therapy (HBOT) as an adjunct treatment for perianal fistulas in Crohn’s disease. It shows substantial improvements in fistula healing, disease activity, and inflammatory markers, with sustained effects over 9 months post-treatment.

This review explores the potential role of Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn’s disease and examines the benefits of anti-MAP therapy (AMT) in treating refractory disease. It discusses recent findings, clinical trial outcomes, and the promising use of novel drug formulations targeting MAP.

This review explores phage therapy as a promising treatment for liver diseases linked to gut microbiota imbalances. It highlights key findings on how phages target harmful bacteria, restoring microbiome balance and improving liver function.

This review examines the impact of dietary zinc on gut microbiota and its role in Clostridium difficile infection. Excess zinc is shown to alter microbiota composition and increase disease severity, underscoring the importance of regulating zinc intake in high-risk populations.

The review explores the role of gut microbiota in immune regulation and pathogen resistance, particularly in inflammatory diseases like IBD. It highlights the effects of microbiota dysbiosis and the potential for therapeutic interventions to manage gut inflammation.

This review examines the impact of iron therapy on oxidative stress and the intestinal microbiota in IBD, highlighting the complexities of managing iron deficiency in these patients. It emphasizes the need for careful iron therapy management to avoid exacerbating oxidative stress and microbial imbalance.

This study examines the genome sequences of copper-resistant Enterococcus faecalis strains isolated from copper-fed pigs. It identifies key resistance genes, highlighting the potential for co-transfer of copper and antibiotic resistance, with implications for agricultural practices and pathogen control.

Copper’s dual role as both an antimicrobial and essential micronutrient plays a significant part in the host-pathogen interaction, with pathogens evolving resistance mechanisms while hosts leverage copper to combat infections. This study offers insights into how copper impacts infection biology, potentially informing new therapeutic strategies.

This study links the Cu/Zn ratio with markers of disease activity in IBD, suggesting it as a potential biomarker for disease monitoring. It emphasizes the role of zinc and copper deficiencies in IBD progression.

The study reveals a higher prevalence of zinc deficiency in Crohn’s disease patients compared to healthy controls. While serum zinc levels did not differ significantly between groups, the increased deficiency rate in CD highlights the need for zinc monitoring and potential supplementation in these patients.

This study highlights the high prevalence of iron deficiency anemia (IDA) in Crohn’s disease patients and its association with worse hospitalization outcomes, including longer stays, higher costs, and more readmissions. The findings stress the need for early IDA screening and management in this population.

This study reveals altered fecal bile acid composition in IBD patients, especially UC, suggesting the potential of bile acids as biomarkers for disease severity and differentiation between UC and CD.

This study links gut microbiota dysbiosis with bile acid composition changes in Crohn’s disease. The altered microbial and bile acid profiles may play a significant role in disease progression, offering potential therapeutic avenues.

This review discusses succinate’s role in IBD pathogenesis, focusing on its dual role in inflammation and tissue repair. The review underscores the importance of microbiota-driven succinate regulation and explores potential therapeutic strategies targeting succinate metabolism in IBD.

This narrative review explores succinate’s dual immunoregulatory roles in IBD, examining how its concentration affects inflammation and tissue repair. The study discusses potential therapeutic strategies targeting succinate metabolism and its signaling pathways.

This review investigates how gut microbiota dysbiosis impacts metabolic functions and immune responses in inflammatory bowel disease (IBD), highlighting key microbial changes and therapeutic potential through microbiome manipulation.

This study reveals the significant role of gut microbiome and metabolome signatures in predicting infliximab response in Crohn’s Disease, suggesting that microbiome-based biomarkers could guide personalized treatment strategies.

This study highlights the complex relationship between the gut microbiota, the immune system, and intestinal health. It emphasizes how disruptions to this balance can lead to chronic diseases like inflammatory bowel disease.

This review examines the environmental and genetic factors influencing Crohn’s disease, offering insight into how these factors contribute to disease onset, progression, and management. The study highlights the increasing incidence in developing countries and the role of diet, smoking, and infections.

This study systematically reviews the use of AI-assisted capsule endoscopy for detecting lesions in Crohn’s disease. AI showed high diagnostic accuracy with a sensitivity of 94% and specificity of 97%, highlighting its potential to improve the diagnostic process, though more research is needed for validation.

This review examines how migration and environmental risk factors influence the onset and course of inflammatory bowel diseases (IBD), with a focus on migrant populations transitioning from low-incidence to high-incidence regions. It emphasizes the need for further studies on generational changes and environmental triggers of IBD.

This review explores environmental factors such as smoking, diet, and air pollution that influence the onset and progression of Crohn’s disease. It highlights the importance of smoking cessation and dietary adjustments in managing the disease.

This review investigates the ongoing debate over the potential role of Mycobacterium avium subspecies paratuberculosis in Crohn’s disease. Despite frequent detection in patients, MAP’s causative role remains unproven, with studies showing inconsistent results, particularly regarding treatment efficacy.

The study examines the debate surrounding Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn’s disease, with conflicting data on its role as a causative factor. Anti-MAP therapies show mixed results, highlighting the need for further investigation into MAP’s involvement in CD pathogenesis.